Autologous
Cell Therapy
Stem Cells

The KOL’s View With Dr Philippe Menasche, University of Paris

Phacilitate
18 May 2020
SHARE NOW

Episode four of the Phacilitate Leaders World 2020 super plenary series

Advanced Therapies Week

2022, Miami, Florida.
Book Today

Episode four of the Phacilitate Leaders World 2020 super plenary series with Dr Philippe Menasche, Professor of Thoracic and Cardiovascular Surgery, University of Paris

If we fail to study history, we are doomed to repeat it…

In this fourth and final instalment of the Phacilitate Leaders World super plenary interviews, Anthony Davies talks to Dr Philippe Menasche who is a true pioneer of stem cell therapy. Back in 2000, he performed an autologous skeletal myoblast transplant, followed by a first in man transplant of human embryonic stem cell-derived cardiovascular progenitor cells in 2014.

What can we learn from the experience of the veterans of our field?

Dr Menasche relays his thoughts on why the term ‘regenerative medicine’ would be better known as reparative medicine and why the exosome is currently fashionable. He’d prefer to see people focusing on the cell-derived secretome, do you agree?

Most importantly, upon considering his possible contribution to other therapeutic areas after a lifetime in the field of cardiology, Philippe states that:

“Cross-fertilisation is really critical, it’s the spirit of this meeting.”

I couldn’t agree with him more.

Advanced Therapies Week

2022, Miami, Florida.
Book Today